Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
FRSW117 Repeat Dosing in Severe Hemophilia A
NCT05265286Phase 2Completed
- Sponsor
- Gensciences
- Start
- Apr 2022
- Primary completion
- Aug 2022
- Modality
- PEGylated Peptides, Fc-Fusion Proteins
- Countries
- 1
01
Overview
A Phase 2 trial of pegylated recombinant human coagulation factor VIII-Fc fusion protein in hemophilia A, sponsored by Gensciences. Started Apr 2022; status: completed.
02
Drugs
pegylated recombinant human coagulation factor VIII-Fc fusion protein
03
Conditions
hemophilia A
Beyond the preview
Go deeper on NCT05265286.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05265286.